Shares of Pharmasset (VRUS) shoot up 8.4% premarket after Morgan Stanley reiterates an...


Shares of Pharmasset (VRUS) shoot up 8.4% premarket after Morgan Stanley reiterates an Overweight rating after taking in the results of a study on the firm's liver disease treatment. The company took a hit Friday, down 11.9%, after rival Inhibitex (INHX) hit a home run with positive data from its hepatitis C drug trial.

From other sites
Comments (1)
  • phoneranger
    , contributor
    Comments (348) | Send Message
     
    QVT, RA and H&Q FTW http://bit.ly/siymfu
    7 Nov 2011, 08:44 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs